Sangamo BioSciences | SGMO - Ebitda


Sangamo BioSciences reported $-67.97M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 5.14B 775M Dec/2025
Bayer EUR 1.51B 1.28B Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 1.96B 1.27B Jun/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Grifols EUR 482.04M 7.04M Sep/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Omeros USD -47.96M 7.39M Sep/2023
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025